Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Uterine Cervical Neoplasms × sitravatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Melanoma 1 Lung Diseases 1 Liposarcoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Squamous Cell 1 Advanced Biliary Tract Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 85 Radiotherapy 45 Brachytherapy 35 Carboplatin 29 Paclitaxel 26 Surveys and Questionnaires 24 pembrolizumab 16 Radiation 16 Magnetic Resonance Spectroscopy 15 Colposcopy 15 Blood Specimen Collection 15 Methods 13 Bevacizumab 13 Drug Therapy 12 Papanicolaou Test 11 Biopsy 11 toripalimab 10 Topotecan 10 Gemcitabine 10 Early Intervention, Educational 10 Radiotherapy, Intensity-Modulated 9 Mass Screening 9 Docetaxel 9 camrelizumab 8 Patient Navigation 8 Papillomavirus Vaccines 8 Educational Status 8 Conization 8 Chemoradiotherapy 8 Nivolumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05614453 2023-06-29

ITTACC

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡